Cardiac assessment of early breast cancer patients 18years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.

Auteurs : de Azambuja E, Ameye L, Diaz M, Vandenbossche S, Aftimos P, Hernández SB, Shih-Li C, Delhaye F, Focan C, Cornez N, Vindevoghel A, Beauduin M, Lemort M, Paesmans M, Suter T, Piccart-Gebhart M
Année : 2015
Journal : Eur J Cancer
Volume : 51
Pages : 2517-24

Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.

Auteurs : Sonnenblick A, Francis PA, Azim HA, de Azambuja E, Nordenskjöld B, Gutiérez J, Quinaux E, Mastropasqua MG, Ameye L, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Barnadas A, Cortes-Funes H, Piccart-Gebhart M, Crown J
Année : 2015
Journal : Eur. J. Cancer
Volume : 51(12)
Pages : 1481-9

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors = 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.

Auteurs : OSullivan CC, Bradbury I, Campbell C, Spielmann M, Perez EA, Joensuu H, Costantino JP, Delaloge S, Rastogi P, Zardavas D, Ballman KV, Holmes E, de Azambuja E, Piccart-Gebhart M, Zujewski JA, Gelber Rd
Année : 2015
Journal : J. Clin. Oncol.
Volume : 33(24)
Pages : 2600-8

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.

Auteurs : Salgado R, Denkert C, Campbell C, Savas P, Nucifero P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, Piccart-Gebhart M, Michiels S, Bradbury I, Sotiriou C, Loi S
Année : 2015
Journal : JAMA Oncol
Volume : 1(4)
Pages : 448-54

Duration of endocrine therapy and its impact on the results of adjuvant trials in premenopausal breast cancer patients.

Auteurs : Fouad TM, de Azambuja E, Azim HA
Année : 2015
Journal : Ann Oncol
Volume : 26(7)
Pages : 1511

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.

Auteurs : Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, + collaborators (among others :, Dal Lago L, de Azambuja E, Dabakuyo-Yonli TS
Année : 2015
Journal : Ann Oncol
Volume : 26(5)
Pages : 873-879.

High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.

Auteurs : Scaltriti M, Nuciforo P, Bradbury I, Sperinde J, Agbor-Tarh D, Campbell C, Chenna A, Winslow J, Serra V, Parra JL, Prudkin L, Jimenez J, Aura C, Harbeck N, Pusztai L, Ellis C, Eidtmann H, Arribas J, Cortes J, de Azambuja E, Piccart-Gebhart M, Baselga J
Année : 2015
Journal : Clin Cancer Res
Volume : 21(3)
Pages : 569-76

PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer.

Auteurs : Majewski IJ, Nuciforo P, Mittempergher L, Bosma AJ, Eidtmann H, Holmes E, Sotiriou C, Fumagalli D, Jimenez J, Aura C, Prudkin L, Díaz-Delgado MC, de la Peña L, Loi S, Ellis C, Schultz N, de Azambuja E, Harbeck N, Piccart-Gebhart M, Bernards R, Baselga J
Année : 2015
Journal : J. Clin. Oncol.
Volume : 33(12)
Pages : 1334-9

Menopausal hormone therapy use in 17 European countries during the last decade.

Auteurs : Ameye L, Antoine C, Paesmans M, de Azambuja E, Rozenberg S
Année : 2014
Journal : Maturitas
Volume : 79(3)
Pages : 287-91

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.

Auteurs : de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios CH, Perez EA, Azim HA, Kim SB, Kuemmel S, Huang CS, Vuylsteke P, Hsieh RK, Gorbunova V, Eniu A, Dreosti L, Tavartkiladze N, Gelber Rd, Eidtmann H, Baselga J
Année : 2014
Journal : Lancet Oncol
Volume : 15(10)
Pages : 1137-46

Reply to C. Fontanella et Al.

Auteurs : Azim HA, de Azambuja E, Agbor-Tarh D, Bradbury I
Année : 2014
Journal : J. Clin. Oncol.
Volume : 32(30)
Pages : 3459

Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives.

Auteurs : Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E, Viale G, Sotiriou C, Piccart-Gebhart M
Année : 2014
Journal : J. Clin. Oncol.
Volume : 32(25)
Pages : 2794-803

Information perception, wishes, and satisfaction in ambulatory cancer patients under active treatment: patient-reported outcomes with QLQ-INFO25.

Auteurs : Pinto AC, Ferreira-Santos F, Dal Lago L, de Azambuja E, Pimentel FL, Piccart-Gebhart M, Razavi D
Année : 2014
Journal : Ecancermedicalscience
Volume : 8(null)
Pages : 425

Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01).

Auteurs : de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, Untch M, Smith IE, Gianni L, Baselga J, Jackisch C, Cameron DA, Bell R, Leyland-Jones B, Dowsett M, Gelber Rd, Piccart-Gebhart M, Suter TM
Année : 2014
Journal : J. Clin. Oncol.
Volume : 32(20)
Pages : 2159-65

Cardiotoxicity of systemic agents used in breast cancer.

Auteurs : Ades F, Zardavas D, Pinto AC, Criscitiello C, Aftimos P, de Azambuja E
Année : 2014
Journal : Breast
Volume : 23(4)
Pages : 317-328

Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): A European survey conducted by the European Society for Medical Oncology (ESMO) Young Oncologists Committee.

Auteurs : Califano R, Karamouzis MV, Banerjee S, de Azambuja E, Guarneri V, Hutka M, Jordan K, Kamposioras K, Martinelli E, Corral J, Postel-Vinay S, Preusser M, Porcu L, Torri V
Année : 2014
Journal : Lung Cancer
Volume : 85(1)
Pages : 74-80

Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: A retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy.

Auteurs : Bozovic-Spasojevic I, Ameye L, Paesmans M, Larsimont D, Di Leo A, Dolci S, Piccart-Gebhart M, de Azambuja E, Loi S
Année : 2014
Journal : Breast
Volume : 23(4)
Pages : 473-81

Controversial Issues in Early Stage Breast Cancer: a Global Collaborative Survey, supported by the European Society for Medical Oncology (ESMO).

Auteurs : Zardavas D, Ades F, Spasojevic IB, Pugliano L, Capelan M, Paesmans M, de Azambuja E, Piccart-Gebhart M
Année : 2014
Journal : Ann Oncol
Volume : 25(8)
Pages : 1558-62

Factors affecting surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial.

Auteurs : Criscitiello C, Azim HA, de Azambuja E, Rubio IT
Année : 2014
Journal : Ann Oncol
Volume : 25(4)
Pages : 910-1

The landscape of medical oncology in Europe by 2020.

Auteurs : de Azambuja E, Ameye L, Paesmans M, Zielinski CC, Piccart-Gebhart M, Preusser M
Année : 2014
Journal : Ann Oncol
Volume : 25(2)
Pages : 525-8